Description
Product details
ST GLIPTIN GM is a high-quality, fixed-dose combination oral antidiabetic medication containing Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg, and Glimepiride 1 mg. This triple-combination therapy is specifically formulated to provide effective glycemic control in adults with type 2 diabetes mellitus (T2DM) who require multiple agents to achieve adequate blood sugar control. ST GLIPTIN GM works through complementary mechanisms to target the core pathophysiological defects of T2DM—insulin resistance, impaired insulin secretion, and increased hepatic glucose output—making it an ideal choice for patients requiring intensified therapy. Key Indications: ST GLIPTIN GM is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when dual therapy with any two of the individual components (Sitagliptin, Metformin, or Glimepiride) does not provide adequate control. Mechanism of Action: Sitagliptin (50 mg): A Dipeptidyl Peptidase-4 (DPP-4) inhibitor that enhances the levels of active incretin hormones (GLP-1 and GIP), increasing insulin release and decreasing glucagon secretion in a glucose-dependent manner. Metformin Hydrochloride (1000 mg): A biguanide that improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake. Glimepiride (1 mg): A sulfonylurea that stimulates pancreatic β-cells to secrete insulin, thereby reducing blood glucose levels. The combination targets multiple metabolic pathways to provide synergistic and sustained blood glucose control. Dosage and Administration: Recommended Dose: One tablet daily, preferably with meals to reduce gastrointestinal side effects. Individualization Required: Dosage should be tailored based on patient response, renal function, and physician assessment. Renal Monitoring: Baseline and periodic assessment of renal function is advised, particularly due to the metformin component. Key Benefits of ST GLIPTIN GM 50/1000/1: Triple Mechanism of Action: Targets insulin resistance, insufficient insulin secretion, and excessive hepatic glucose production. Enhanced Glycemic Control: Effective in achieving and maintaining HbA1c targets. Once-Daily Convenience: Improves adherence by reducing pill burden in patients requiring combination therapy. Weight Neutral to Modest Reduction: Metformin and sitagliptin components support weight neutrality. Low Hypoglycemia Risk: Sitagliptin and metformin carry minimal hypoglycemia risk; however, glimepiride may increase the risk—monitor accordingly. Safety and Precautions: Hypoglycemia: May occur, particularly due to the glimepiride component. Educate patients on recognizing and managing low blood sugar. Lactic Acidosis: A rare but serious complication of metformin. Avoid in patients with significant renal impairment or conditions predisposing to hypoxia. Renal Function: Dose adjustment or discontinuation may be needed based on renal function. Pancreatitis: Rare reports with DPP-4 inhibitors like sitagliptin. Discontinue if suspected. Allergic Reactions: Discontinue use if hypersensitivity reactions occur. Possible Side Effects: While ST GLIPTIN GM is generally well-tolerated, some patients may experience: Nausea Diarrhea Headache Hypoglycemia (especially in elderly or with missed meals) Abdominal discomfort Upper respiratory tract infections Dizziness Flatulence If any side effects persist or worsen, seek immediate medical advice. Storage Instructions: Store at a temperature below 30°C. Protect from moisture and direct sunlight. Keep out of reach of children. Why Choose ST GLIPTIN GM 50/1000/1? ST GLIPTIN GM provides a powerful and synergistic combination of three well-established antidiabetic agents in a single, convenient daily dose. It offers a comprehensive approach to managing type 2 diabetes by addressing multiple metabolic abnormalities with a focus on safety, efficacy, and patient compliance. Manufactured under stringent GMP-certified conditions, ST GLIPTIN GM ensures quality, reliability, and therapeutic confidence for both patients and prescribers.
